Bosentan alleviates the pro-fibrotic phenotype of lung scleroderma fibroblasts: Implications for treatment of scleroderma.
Autors principals: | Leask, A, Xu, S, Renzoni, E, Bou-Gharios, G, du Bois, R, Abraham, D, Black, C |
---|---|
Format: | Conference item |
Publicat: |
2005
|
Ítems similars
-
Bosentan attenuates the profibrotic gene expression profile of lung fibroblasts in scleroderma
per: Shiwen, X, et al.
Publicat: (2006) -
Effects of bosentan on collagen type I synthesis on in vitro culture of scleroderma skin fibroblasts
per: S. Soldano, et al.
Publicat: (2011-01-01) -
Successful Treatment with Bosentan of Lower Extremity Ulcers in a Scleroderma Patient
per: Alix Naert, et al.
Publicat: (2013-01-01) -
CTGF overexpressing mice: a model for human scleroderma
per: Sonnylal, S, et al.
Publicat: (2006) -
Bosentan Does Not Affect Renal Resistive Index in Scleroderma/Systemic Sclerosis Patients
per: Emma Di Poi, et al.
Publicat: (2023-11-01)